Anti-Proteinuric Effect of Sulodexide in Immunoglobulin A Nephropathy

作者：Bang Kitae; Chin Ho Jun; Chae Dong Wan; Joo Kwon Wook; Kim Yon Su; Kim Suhnggwon; Ju Kyung Don; Kim Hwajung; Ahn Curie; Oh Kook Hwan^*

来源：Yonsei Medical Journal, 2011, 52(4): 588-594.

DOI：10.3349/ymj.2011.52.4.588

• IgA nephropathy
• sulodexide
• proteinuria

Purpose: We conducted a multi-center randomized double-blind study to determine the effects of 6-month therapy with sulodexide on urinary protein excretion in patients with idiopathic Immunoglobulin A (IgA) nephropathy. Materials and Methods: A total of seventy-seven patients participated in the study. They were randomly allocated to one of three groups: sulodexide 75 mg or 150 mg daily or the placebo for 6 months. The primary end point was the achievement, at 6 months, of at least 50% reduction in urine protein/creatinine ratio (UPCR) from the baseline value. Results: At 6 months, the primary end point was achieved by 12.5% of the patients assigned to the placebo, 4.0% of the patients assigned to sulodexide 75 mg daily and 21.4% of those assigned to 150 mg (p=0.308). Treatment with sulodexide 150 mg daily for 6 months significantly reduced log UPCR from 6.38 +/- 0.77 at baseline to 5.98 +/- 0.94 at 6 months (p=0.045), while treatment with sulodexide 75 mg daily and placebo did not. Conclusion: A 6-month treatment with sulodexide did not achieve 50% reduction of urinary protein excretion in IgA nephropathy patients, but showed a tendency to increase the time-dependent anti-proteinuric effect. Therefore, long-term clinical trials on a larger scale are warranted to elucidate the hypothesis that sulodexide affords renal protection in IgA nephropathy patients.

• 出版日期2011-7-1